Observational study of the clinical utility of sulfamethoxazole serum level monitoring in the treatment of brain abscesses due to *Nocardia* species

Cristina Corsini Campioli, MD,*,†, Omar Abu Saleh, MD, Kristin C. Mara, MS, Christina G. Rivera, PharmD, RPh

**Abstract**

Although there is a lack of data in trimethoprim-sulfamethoxazole (TMP-SMX) serum monitoring utility for invasive nocardial infections, therapeutic drug monitoring is widely used to optimize dosing and avoid adverse reactions that may cause treatment interruption.

We retrospectively reviewed all adults who received TMP-SMX to treat nocardial brain abscess and had SMX serum level testing from 2010 to 2020. Twenty-two patients received treatment with TMP-SMX for *Nocardia* species brain abscess and 16 (72.7%) had a reported SMX level, with a median patient age of 65.5 years (interquartile range, IQR 59.5–72.5). Compared to those who did not have a documented SMX serum level, patients with SMX levels had a shorter median course of TMP-SMX treatment (322 days [IQR 188–365] vs. 365 [IQR 224–365]; *P* = .31) and higher therapeutic induction dose (10 [62.5%] vs. 3 [50%]; *P* = .92). Similarly, they were more frequently on hemodialysis (3 [13.6%] vs. 1 [4.5%]; *P* = .99). The median peak level was 158.5 (IQR 120–218) μg/mL, collected at 2 hours (75% post-administration in the induction phase [81.3%]). Patients with documented SMX levels had fewer reported drug toxicity (5 [31.3%] vs. 4 [66.7%]; *P* = .1) than those without SMX levels. Among the five patients who reported TMP-SMX-related toxicity, 4 (80%) had an SMX peak level >150 μg/mL. There was no difference in the cure, relapse, and death rates among the two groups.

While SMX level was not associated with *Nocardia* species brain abscess cure rates and mortality, most patients with SMX peak >150 μg/mL experienced drug toxicity.

**Abbreviations:** AKI = acute kidney injury, IQR = interquartile range, spp. = species, TMP-SMX = trimethoprim-sulfamethoxazole

**Keywords:** brain abscess, nocardia, outcomes, serum level, sulfamethoxazole

## 1. Introduction

Despite the introduction of newer antibiotics, diagnostics, and therapeutic procedures, the mortality rates for nocardial brain abscesses remain high, up to 30%, compared to 10% for other bacterial causes.[1,2] The treatment choice remains challenging, as there are no randomized clinical trials to compare the efficacy of different antibiotic regimens for nocardiosis; however, the well-known active agents against *Nocardia* species (spp.) are trimethoprim-sulfamethoxazole (TMP-SMX), amikacin, minocycline, and imipenem.[3] Sulfonamides and trimethoprim are small lipophilic antibiotics. At high doses (5 mg of TMP and 25 mg of SMX per kg of body weight), the penetration into the cerebrospinal fluid is considered sufficient for treating central nervous system infections.[4,5] Currently, TMP-SMX is viewed as the mainstay of therapy in susceptible isolates.[6]

Since TMP-SMX has consistently demonstrated significant interindividual pharmacokinetics variability, therapeutic drug monitoring is often used to optimize dosing and avoid adverse reactions that may contribute to treatment interruption.[7] While data exists on the use of SMX level monitoring for *Pneumocystis jirovecii* pneumonia,[8] there is a lack of data in SMX serum monitoring utility for invasive nocardial infections. Therefore, we aimed to describe the clinical utility of SMX serum level monitoring in treating brain abscesses due to *Nocardia* spp. in a contemporary cohort at a large referral center.

## 2. Materials and methods

We retrospectively reviewed all adult (≥18 years of age) patients who received TMP-SMX to treat nocardial brain abscess and
underwent SMX testing levels from January 1, 2009 through June 30, 2020. Patients’ electronic health records were reviewed. All the patients had consented to use their medical records for research purposes, and the study was approved by the Mayo Clinic Institutional Review Board (IRB# 21-001470).

A search was conducted using an Advanced Cohort Explorer tool developed by Mayo Clinic using “brain abscess.” Case definitions, microbiologic information, and variables included in this database have been described in earlier publications.\(^\text{10}\) Polymicrobial infections were excluded.

The SMX peak was defined as the level obtained 1 hour after the intravenous dose, or 2 to 3 hours after an oral dose. A peak of 100 to 150 μg/mL has been suggested as the target for SMX levels in nocardial infections.\(^\text{10}\) Higher TMP-SMX therapeutic dose was defined as two double strength tablets twice or three times a day; whereas a lower therapeutic dose was defined as one double strength tablet a day or three times a day. Oral double-strength tablet dosage was 160 mg TMP/800 mg SMX and, intravenous dosage was 80 mg TMP/400 mg SMX per 5 mL. Laboratory assessment SMX serum concentration levels were determined by liquid-chromatography mass spectrometry by our institution’s Clinic Toxicology and Drug Monitoring Laboratory.\(^\text{11}\) Failure was defined as a relapse, brain abscess size progression, or the development of a new abscess with the same bacterial etiology within 3 months despite initial medical or surgical therapy. Acute kidney injury (AKI) for patients who did not have chronic kidney disease was defined as an increase in the serum creatinine concentration of ≥0.3 mg/dL from baseline, a percentage increase in the serum creatinine concentration of ≥50% or oliguria. For patients with chronic kidney disease, AKI was defined as an increase in serum creatinine of ≥50%.\(^\text{12}\) Of note, the patients with an initially normal renal function also needed to have an increase in Blood Urea Nitrogen of 10 mg/dL.\(^\text{13,14}\)

### 2.1. Statistical analysis

Descriptive information about patients with brain abscesses was reported as frequencies and percentages for categorical variables or median (interquartile range [IQR]) for continuous variables. Statistical tests were 2-tailed, with \(P<.05\) considered statistically significant. Statistical analysis was performed using BlueSky Statistics software v7.2 (BlueSky Statistics LLC, Chicago, IL).

### 3. Results

#### 3.1. Demographic and radiologic characteristics

Comparisons of demographic, comorbidities, and radiographic characteristics of patients with Nocardia spp. brain abscess with and without SMX levels are summarized in Table 1. Overall, 24 patients were diagnosed with Nocardia spp. brain abscess. Of them, 22 (91.7%) were treated with TMP-SMX, and 16 (72.7%) had a documented SMX level. Medical comorbidities were similar for both groups, including diabetes mellitus, chronic kidney disease, and vascular disease. Compared to those who did not have a documented SMX serum level, there was a higher percentage of patient with hemodialysis in the SMX levels group (hemodialysis, 3 [13.6%] vs. 1 [4.5%]); however, this difference was not statistically significant. None of 22 patients had a preexisting central nervous system hardware.

At the time of admission, no statistically significant differences were observed in the radiologic characteristics that included the

| Table 1 | Demographic, comorbidities, and radiographic characteristics of patients with Nocardia species brain abscess with and without SMX levels. |
|---------|----------------------------------------------------------------------------------------------------------------------------------|
|         | No SMX levels (n = 6) | SMX levels (n = 16) | Total (n = 22) | \(P^\text{\textdagger}\) |
| Age median (IQR), y | 61.5 (50–64) | 65.5 (59.5–72.5) | 64 (58–69) | .16 |
| Male, n (%) | 3 (50) | 14 (87.5) | 17 (77.3) | .10 |
| White Race, n (%) | 5 (83.3) | 15 (93.8) | 20 (90.9) | .48 |
| Prior head/neck surgery, n (%) | 0 (0) | 2 (12.5) | 2 (9.1) | >.99 |
| Comorbidities, n (%) | | | | |
| Diabetes mellitus | 3 (50) | 4 (25) | 7 (31.8) | .65 |
| Malignancy | 2 (33.3) | 8 (50) | 10 (45.5) | |
| History of stroke | 0 (0) | 1 (6.3) | 1 (4.5) | |
| Immunosuppressive therapy | 4 (66.7) | 9 (56.3) | 13 (59.1) | |
| Bone marrow transplant | 2 (33.3) | 1 (6.3) | 3 (13.6) | |
| Solid organ transplant | 3 (50) | 4 (25) | 7 (31.8) | |
| Hypertension | 2 (33.3) | 5 (31.3) | 7 (31.8) | |
| Chronic kidney disease | 3 (50) | 7 (43.8) | 10 (45.5) | |
| Hemodialysis | 1 (4.5) | 3 (13.6) | 4 (18.2) | >.99 |
| CCI, median (IQR) | 6 (4–9) | 7 (5–10) | 7 (5–10) | .74 |
| Brain abscess location, n (%) | | | | |
| Frontal lobe | 2 (33.3) | 7 (43.8) | 9 (40.9) | >.99 |
| Temporal lobe | 4 (66.7) | 3 (18.8) | 7 (31.8) | .05 |
| Parietal lobe | 2 (33.3) | 6 (37.5) | 8 (36.4) | >.99 |
| Occipital lobe | 1 (16.7) | 4 (25) | 5 (22.7) | >.99 |
| Fluid collection size, median, cm (IQR) | 1.8 (1–2.1) | 1.3 (0.9–2.15) | 1.5 (1–2.1) | .58 |
| Midline shift, n (%) | 1 (16.7) | 1 (6.3) | 2 (9.1) | .48 |
| Single fluid collection, n (%) | 3 (50) | 11 (68.8) | 14 (63.6) | .62 |

\(\text{CCI} = \text{Charlson Comorbidity Index}; \text{IQR} = \text{interquartile range}; \text{n} = \text{number}; \text{SMX} = \text{sulfamethoxazole}; \text{y} = \text{years}.\)

* Fisher’s test.

\(\dagger\) Mann–Whitney U test.
presence of brain midline shift (6.3% vs. 16.7%; \( P = .48 \)), the median size of the fluid collection (1.3 cm [IQR 0.9–2.1] vs. 1.8 cm [IQR 1–2.1]; \( P = .58 \)) and the presence of a single fluid collection (68.8% vs. 50%; \( P = .62 \)).

### 3.2. Management

A total of 10 (45.5%) patients had a therapeutic surgical intervention (7 [43.7%] in those with SMX levels, vs. 3 [50%] without SMX levels; \( P \geq .99 \)). There was no difference in the overall median time from brain abscess diagnosis to surgical management, which was 5 days (IQR 0–73) and 7 days (IQR 1–9) in each group, respectively. All patients had an infectious diseases consultation during their hospitalization.

Compared to those without a documented SMX serum level, patients with SMX levels had a shorter median course of treatment with TMP-SMX (322 days [IQR 188–365] vs. 365 days [IQR 224–365]; \( P = .31 \)), and higher therapeutic dose (10 [62.5%] vs. 3 [50%]; \( P = .92 \)), both statistically nonsignificant.

Individual characteristics of patients treated with TMP-SMX for *Nocardia* species brain abscess is summarized in Table 2. A total of 7 patients (32%) received TMP-SMX monotherapy as their final antibiotic therapy. In patients where SMX levels were obtained, a total of 9 (41%) patients reported TMP-SMX-related toxicity. Compared to those who did not have a documented SMX serum level, a numerically lower (nonsignificant) percentage of patients with documented SMX levels had reported drug toxicities (5 [31.3%] vs. 4 [66.7%]; \( P = .1 \)), and the most common included nausea (3 [60%] vs. 1 [25%]; \( P = .5 \)), AKI (1 [20%] vs. 2 [50%]; \( P = .5 \)), and thrombocytopenia (1 [20%] vs. 1 [25%]; \( P \geq .99 \)), respectively. Among the five patients with documented SMX levels who reported TMP-SMX-related toxicity, 4 (80%) had a SMX peak level \( > 150 \mu g/mL \) (AKI \( n = 1 \), thrombocytopenia \( n = 1 \), and nausea \( n = 2 \)); Supplementary Table 1, http://links.lww.com/MD/G628). Of note, toxicity was not associated with mg/kg/day TMP dose.

A total of 14 (9 [56.3%] vs. 5 [83.3%]) patients were cured, 4 (3 [18.8%] vs. 1 [16.7%]) relapsed, and 2 (2 [12.5%] vs. 0 [0%]) died, when comparing groups with and without SMX levels, respectively (\( P = .9 \)). The patients with death or relapse were more likely to be a higher mg/kg/day dose TMP than those who were cured (\( P = .006 \); Supplementary Table 2, http://links.lww.com/MD/G629).

### 3.3. Outcomes

A total of 9 (41%) patients reported TMP-SMX-related toxicity. Compared to those who did not have a documented SMX serum level result. For second sulfa level assessment, most frequent recommendation (50%) was to continue therapy based on the first level results followed by decreased TMP-SMX dose (37.5%). Only one patient had an increased dose based on sulfa level result. For second sulfa level assessment, most frequent response was to decrease TMP-SMX dose (50%).

### Table 2

| Patient/HD (y) | Dose | Therapy | Route | Time | SMX peak level | Dosing modification | Cure (y/n) | Toxicity (y/n) |
|---------------|------|---------|-------|------|----------------|---------------------|------------|---------------|
| 1             | 1 DS TID Induction | Oral | 2   | 123  | Continue       | y       | n           |
| 2/y           | 2 DS TID Induction | Oral | 2   | 276  | Decrease       | 1       | 264 Decrease |
| 3             | 2 DS TID Induction | Oral | 2   | 190  | Decrease       | 2       | n           |
| 4             | 2 DS BID Induction | Oral | 2   | 199  | Decrease       | 2       | 157 Continue |
| 5             | 1 DS TID Induction | Oral | 1   | 245  | Decrease       | n       | y           |
| 6             | 1 DS TID Induction | Oral | 3   | 92   | Continue       | 3       | 168 Decrease |
| 7             | 2 DS TID Induction | Oral | 2   | 166  | Continue       | n       | n           |
| 8/y           | 1 DS TID Induction | IV   | 2   | 102  | Continue       | 2       | 135 Continue |
| 9             | 2 DS BID Induction | Oral | 2   | 120  | Continue       | y       | n           |
| 10            | 1 DS BID Induction | Oral | 3   | 12   | Increase       | n       | n           |
| 11            | 2 DS TID Induction | Oral | 2   | 226  | Decrease       | 2       | 256 Decrease |
| 12            | 2 DS BID Induction | Oral | 2   | 120  | Continue       | y       | n           |
| 13/y          | 2 DS BID Induction | IV   | 2   | 210  | Hold           | 2       | 62 Increase  |
| 14            | 1 DS BID Induction | Oral | 3   | 282  | Decrease       | y       | y           |
| 15            | 2 DS TID Induction | Oral | 2   | 151  | Continue       | 2       | 173 Decrease |
| 16            | 2 DS BID Induction | Oral | 2   | 145  | Continue       | 2       | 159 Continue |

**Notes:**
- BD = twice a day, DS = double strength, HD = hemodialysis, IV = intravenous, n = no, PO = oral, SMX = sulfamethoxazole, TID = three times a day, y = yes.
- \( ^{\dagger} \) Sampling: hours post-dosing administration
- \( ^{\ddagger} \) \( \mu g/mL \)
- \( ^{\ast} \) Toxicities included nausea, thrombocytopenia, and acute kidney injury.
concentrations of SMX. Hence, appropriate drug dosing and monitoring are recommended.\textsuperscript{[18]}

In patients with \textit{Pneumocystis jirovecii} pneumonia, Chin et al.\textsuperscript{[17]} and Blaser et al.\textsuperscript{[19]} demonstrated that divided doses of 2.5 to 50 mg/kg per day of the SMX component produce sulfonamide serum concentrations between 100 and 150 \(\mu\text{g/mL}\). This observation has been extrapolated to drug efficacy regardless of the prescribed dose. Although earlier studies have found that individual SMX level monitoring has no effect in limiting toxicity,\textsuperscript{[19,20]} adverse events are a significant concern in patients that require high SMX doses in the setting of life-threatening diseases such as central nervous system infections, when higher and frequent doses are often recommended.\textsuperscript{[21]} Klinker et al recommended monitoring SMX levels in patients with \textit{Pneumocystis} pneumonia to reduce adverse effects based on their finding of increased toxicity from higher SMX (200 \(\mu\text{g/mL}\) levels).\textsuperscript{[22]} As seen in our cohort, the median SMX peak level was 158.5 \(\mu\text{g/mL}\), and the majority (80\%) of the patients with an SMX peak level >150 \(\mu\text{g/mL}\) had a documented TMP-SMX-related toxicity regardless of the prescribed dose. Higher serum SMX concentration associates with toxicity; hence, obtaining SMX level is helpful in this regard which is also concordant to previous clinical studies.\textsuperscript{[23]} TMP-SMX therapy-related toxicity is frequent. They often include myelosuppression, hepatic toxicity, and renal insufficiency.\textsuperscript{[24]} Not obtaining drug levels and choosing reduced versus conventional standard doses of TMP-SMX to cause less toxicity is not supported by any evidence.

Even though no statistically significant differences in patients’ curative or mortality outcomes between TMP-SMX doses and frequent SMX level monitoring have been reported,\textsuperscript{[8–10]} more diligent drug monitoring in patients with higher and frequent dosages could counteract the aforementioned toxicity concerns. The study’s retrospective nature with a case determination based on the claim dataset is the primary limitation. Likely due to the small size of our cohort, we were unable to report statistically significant results; however, we provide hypothesis generating data and potentially valuable information on therapeutic drug monitoring for an uncommon disease state in clinical practice. Similarly, the peak SMX concentrations from both oral and intravenous administration were combined for analysis, which may lead to difficulties in interpretation. As observed in our study, the patients with higher mg/kg TMP doses were more likely to have worse outcomes; nevertheless, selection biases could have influenced the decision for higher therapeutic doses in sicker patients or those with severe disease.

5. Conclusion

Majority of patients with SMX peak >150 \(\mu\text{g/mL}\) experienced drug toxicity; hence, SMX level monitoring may be helpful for drug toxicity monitoring in patients with \textit{Nocardia} spp. brain abscess.

Author contributions

Cristina Corsini Campioli: Conceptualization; Data curation; Formal analysis; Investigation; Methodology; Visualization; Roles/Writing – original draft; Writing – review & editing

Omar Abu Saleh: Writing – review & editing

Kristin C. Mara: Data curation

Christina G. Rivera: Visualization; Supervision; Writing – review & editing

Conceptualization: Cristina Corsini Campioli.

Data curation: Cristina Corsini Campioli, Kristin C. Mara.

Formal analysis: Cristina Corsini Campioli, Kristin C. Mara.

Investigation: Cristina Corsini Campioli.

Methodology: Cristina Corsini Campioli.

Visualization: Cristina Corsini Campioli, Christina G. Rivera.

Writing – original draft: Cristina Corsini Campioli.

Writing – review & editing: Cristina Corsini Campioli, Omar Abu Saleh, Christina G. Rivera.

References

[1] Brouwer MC, Coutinho JM, van de Beek D. Clinical characteristics and outcome of brain abscess: Systematic review and meta-analysis. Neurology 2014;82:806–13.

[2] Cassir N, Million M, Nould R, Drancourt M, Brouqu P. Sulfonamide resistance in a disseminated infection caused by \textit{Nocardia wallacei}: a case report. J Med Case Rep 2013;7:103.

[3] Hamdi AM, Fida M, Deml SM, Abu Saleh OM, Wengenack NL. Retrospective analysis of antimicrobial susceptibility profiles of \textit{Nocardia} species from a tertiary hospital and reference laboratory, 2011 to 2017. Antimicrob Agents Chemother 2020;64: e01868-19.

[4] Nau R, Sörgel F, Eifert H. Penetration of drugs through the blood–cerebral spinal fluid/blood-brain barrier for treatment of central nervous system infections. Clin Microbiol Rev 2010;23:858–83.

[5] Albert F, Bishop-Freudling GB, Vergin H. [Diffusion of tetroxoprim and sulfadiazine in the cerebrospinal fluid of neurosurgery patients]. Fortschr Med 1984;102:1064–6.

[6] Rosman Y, Grossman E, Keller N, et al. Nocardiosis: a 15-year experience in a tertiary medical center in Israel. Eur J Intern Med 2013;24:552–7.

[7] Medina I, Mills J, Leong G, et al. Oral therapy for \textit{Pneumocystis carinii} pneumonia in the acquired immunodeficiency syndrome. A controlled trial of trimethoprim-sulfamethoxazole versus trimethoprim-dapsone. N Engl J Med 1990;323:776–82.

[8] Butler-Laporte G, Smyth E, Amar-Zifkin A, Cheng MP, McDonald EG, Lee TC. Low-dose TMP-SMX in the treatment of \textit{Pneumocystis jirovecii} pneumonia: a systematic review and meta-analysis. Open Forum Infect Dis 2020;7:ofaa112.

[9] Corsini Campioli C, Castillo Almeida NE, O’Horo JC, et al. Clinical presentation, management, and outcomes of patients with brain abscess due to \textit{Nocardia} species. Open Forum Infectious Diseases 2021;8: ofab067.

[10] Wilson JW. Nocardiosis: updates and clinical overview. Mayo Clin Proc 2012;87:403–7.

[11] Mayo Clinic Laboratories. Sulfamethoxazole, serum. [Available at: http://www.mayomedicallaboratories.com/test-catalog/Overview/8238. Accessed January 11, 2022.]

[12] Mehta RL, Kellum JA, Shah SV, et al. Acute Kidney Injury Network: An updated approach to practice and research: The AKIN workgroup. Crit Care 2007;11:R31.

[13] Horo JC, et al. Clinical pharmacokinetics of \textit{Nocardia} asteroides complex infections. Infect Dis Clin Pract 2007;15:206–13.

[14] Fraser TN, Avellaneda AA, Graviss EA, Musher DM. Acute kidney injury associated with trimethoprim/sulfamethoxazole. J Antimicrob Chemother 1995;36:284–9.

[15] Mceen MM, Brown JM, Hutwagner LC, Schiff TA. Evaluation of therapy for \textit{Nocardia asteroides} complex infections. Infect Dis Clin Pract 1995;4:287–92.

[16] Paap CM, Nahata MC. Clinical use of trimethoprim/sulfamethoxazole during renal dysfunction. DICP 1989;23:646–54.

[17] Chin TW, Vandenbroucke A, Fong JW. Pharmacokinetics of trimethoprim-sulfamethoxazole in critically ill and non-critically ill AIDS patients. Antimicrob Agents Chemother 1995;39:28–33.

[18] Blaser J, Joos B, Opravil M, Luthy R. Variability of serum concentrations of trimethoprim and sulfamethoxazole during high dose therapy. Infection 1993;21:206–9.

[19] Joos B, Blaser J, Opravil M, Chave JP, Luthy R. Monitoring of co-trimoxazole concentrations in serum during treatment of \textit{Pneumocystis carinii} pneumonia. Antimicrob Agents Chemother 1995;39:2661–6.

[20] Ice LL, Barreto JN, Dao BD, et al. Relationship of sulfamethoxazole therapeutic drug monitoring to clinical efficacy and toxicity: a retrospective cohort study. Ther Drug Monit 2016;38:319–26.
[21] Anagnostou T, Arvanitis M, Kourkoumpetis TK, Desalermos A, Carneiro HA, Mylonakis E. Nocardiosis of the central nervous system: experience from a general hospital and review of 84 cases from the literature. Medicine (Baltimore) 2014;93:19–32.

[22] Klinker H, Langmann P, Zilly M, Richter E. Drug monitoring during the treatment of AIDS-associated *Pneumocystis carinii* pneumonia with trimethoprim-sulfamethoxazole. J Clin Pharm Ther 1998;23:149–54.

[23] Dao BD, Barreto JN, Wolf RC, Dierkhising RA, Plevak MF, Tosh PK. Serum peak sulfamethoxazole concentrations demonstrate difficulty in achieving a target range: a retrospective cohort study. Curr Ther Res Clin Exp 2014;76:104–9.

[24] Hell K. Adverse reactions to Bactrim—a retrospective view. Infection 1987;15(Suppl 5):S227–30.